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INTRODUCTION 
When facing dangerous environmental situations, most animal 
species react with a sympathoadrenergic "fight or flight" 
activation; others - like the >qpossum - react with a vagal 
sympathoiiihibitory discharge, or "playing dead" reaction, which 
in this way discourages possible predators. The myocardium 
reacts to dangerous situations with an opossum-like behavior. In 
several "altered myocardial states" (ischemia, hibernation, 
stunning), when the local supply-demand balance of the cell is 
critically endangered, the cell minimizes energy expenditure used 
for development of contractile force (accounting at rest for about 
60% of the high energy phosphates produced by cell metabolism) 
and utilizes whatever is left for the maintenance of cellular 
integrity. The echocardipgraphic counterpart of this cellular 
strategic choice is the regional asynergy of viable segments. The 
depressed function is undistinguishable from infarction state: but, 
differently from necrosis, the segmental dysfunction can be 
transiently normalized by the proper inotropic stimulus. 
A blurred transition zone exists between the fully reversible 
ischemia and the ischemia lasting more than 15-20 minutes 
invariably associated with necrotic phenomena. Within this gray 
zone, ischemia is too sihort to cause myocardial necrosis but long 
enough to induce a persistent contractile dysfunction - lasting for 
hours, days and even weeks - after the restoration of flow: the so 
called myocardial stunning. The stunned myocardium is different 
from "hibernated" myocardium, in which myocardial perfusion is 
chronically reduced (for months or years), but remains beyond the 
critical threshold indispensable to keep the tissue viable - although 
with depressed performance. While in the stunned myocardium a 
metabolic alteration causes an unbalance between energy supply 
and produced work, the hibernating myocardial cell adapts itself 
to a chronically reduced energy supply, and its survival is 
guaranteed by a reduced or abolished contractile function. 
Rahimtoola referred to the hibernating heart as a "smart heart", 
appropriately down-regulating its biochemical and physiological 
activity as an act of self preservation aimed at ensuring the long-
term survival of the anatomical and physiological integrity of its 
constituent cardiac cells. 
The persistent but reversible post-ischemic dysfunction was 
initially an experimental observation - described by Heyndrix and 
later popularized with the successful term of myocardial stunning 
by iBraunwald in 1982. Conversely, myocardial hibernation was a 
clinical impression - copyrighted by a cardiac surgeon, 
Rahimtoola, to describe hearts with severely depressed resting 
preoperative function spectacularly recovering following 
revascularization. 
Although their separation is clear-cut from the conceptual and 
pathophysiologic viewpoint, stunning and hibernation are 
sometimes undistinguishable in the clinical setting. They can 
coexist in the same patient in space (with islands of hibernated and 
stunned tissue interspersed with necrotic and/or normal cells) and 
in time ¡(with early phenomena of'acute stunning progressively 
leading to chronic hibernation, as it may occur after an> acute 
myocardial infarction with critical residual stenosis of the infarct 
related: artery). What ¡is clinically; important is the separation 
between ;asynergic viable and asynergic but necrotic segments. 
The clinical cardiologist can address this issue with a variety of 
imaging . techniques,' including nuclear i and echocardiography 
methods. The markedly hypokinetic or akinetic region, which is 
the target of our diagnostic efforts of recognition of myocardial 
viability can have a continuous spectrum of damage, from mild to 
irreversible.. The different diagnostic probes sample different 
markers of viability cascade. If a function is strictly essential to 
cell survival - for instance, cell membrane integrity - it will be lost 
only for advanced, close to irreversible, degrees of 'daimage. 
Conversely, cither functions, such as functional.response to low 
level inotropic stimulation, indicate that the damage is limited, .and 
the segment is highly likely to recover.. The hibernation has 
different depth; like sleep stages, which' correspond to different 
progressive levels of myocardial damage and decreasing chances 
of detecting a prompt functional recovery,upon revascularization . 
segments. Accordingly, the principal aim of our work was to 
develop alternative pharmacological stress echocardiography 
methods for viability detection: 
1. To assess the potential of an "infra-low1 dose of dipyridamole 
to selectively identify myocardial viability, independently 
evaluated by low dose dobutamine. 
2. To determine the flow-function relationship during coronary 
vasodilatory stress in patients with coronary artery disease 
and baseline dysfunction. 
3. To evaluate the effects of combined administration of iii&a-
low dose dipyridamole and low dose dobutamine on 
assessment of myocardial viability. 
4. To investigate the relation between radioisotopic and 
echocardiography markers of myocardial viability and their 
correlation with functional recovery after coronary 
revascularization. 
5. To :assess the prognostic value of myocardial viability 
recognized as a contractile response to vasodilator stimulation 
in patients with left ventricular dysfunction in a large scale, 
prospective, multicentre, observational study. 
RESULTS 
1. Forty patients with history of myocardial infarction, 
angiographically proven coronaiy artery disease, and resting wall 
motion dyssynergy on the left ventricle were studied with low dose 
dobutamine echo (5p/kg/min followed by 10 pg/Kg/min, each step 
lasting 3 min) and with an infra-low dose dipyridamole (0.28 
mg/Kg over 4 min) echocardiography. Coronary revascularization 
was iperformed in 22 patients. Of the 243 segments with baseline 
dyssynergy, 70 were responders (improved wall motion) with both 
dipyridamole and dobutamine, 157 were non responders with both 
dipyridamole and dobutamine; and 16 showed discordant results. 
The overall concordance of dipyridamole and dobutamine was 
93%. Using funcional recovery after revascularization as a gold 
standard, The sensitivity of dipyridamole and dobutamine was 
76% and 78%, respectively (p=ns). The specificity of both tests 
was 94%. 
2. Thirty:four patients with rest wall motion dyssynergy by 
two-dimensional echocardiography and with angiographically 
proved coronary artery disease underwent in combination with 
two-dimensional echocardiography monitoring: 1) low dose (5 to 
10 pg/Kg per min over . 3 min) dobutamine infusion; 2) infra-low 
dose (0.28 mg/Kg over 4 min) dipyridamole infusion; 3) 
combination of infra-low dose dipyridamole infusion immediately 
followed by low 
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